ECHDC3 Knockout A-549 Polyclonal Cells are CRISPR/Cas9-edited polyclonal knockout cell populations derived from human A-549 lung epithelial carcinoma cells, with targeted disruption of the ECHDC3 gene. This model enables investigation of mitochondrial fatty acid ??-oxidation in a lung adenocarcinoma context. The polyclonal nature avoids clonal bias and maintains genetic heterogeneity, making it suitable for studying population-level metabolic responses.
The A-549 cell line is a standard in vitro model of type II pulmonary epithelial cells, originating from a lung carcinoma of a 58-year-old male. Widely used in cancer biology and drug development, A-549 cells retain key oncogenic features and metabolic adaptability, providing a relevant host for studying lipid metabolism in lung adenocarcinoma.
ECHDC3 encodes a putative mitochondrial enoyl-CoA hydratase that functions in the ??-oxidation pathway, interacting with HADHA, HADHB, and ECHS1 within the fatty acid oxidation complex. Upstream, the PPARA/PGC-1??/AMPK axis activates ECHDC3 expression, linking it to nutrient sensing and energy homeostasis. Downstream, ECHDC3 activity supports acetyl-CoA production, mitochondrial respiration, and lipid accumulation. The ??-oxidation cascade includes CPT1A and ACADVL upstream of ECHDC3, and the electron transfer flavoprotein (ETF) downstream. Disruption of ECHDC3 impairs fatty acid catabolism, potentially shifting cellular energy reliance.
In A-549 cells, fatty acid oxidation contributes to tumor cell proliferation and survival. ECHDC3 knockout creates a loss-of-function model to assess metabolic vulnerabilities, offering a tool to uncover dependencies on mitochondrial ??-oxidation in lung adenocarcinoma. Given the metabolic plasticity of lung adenocarcinoma cells, ECHDC3 ablation may expose vulnerabilities that can be targeted with small-molecule inhibitors, making this model valuable for drug discovery. This model can reveal synthetic lethal interactions or sensitivities to metabolic inhibitors.
Key applications include Seahorse metabolic flux analysis, radiolabeled fatty acid oxidation assays, lipidomics, and high-content viability screens under lipid-rich conditions. Western blotting, RT-qPCR, and MitoTracker staining enable pathway validation. This polyclonal pool is ideal for cancer metabolism research, drug target validation, and metabolic vulnerability screening. For further information, contact Ascent Research.
